COLGATE
GenericsCOLGATE is a generic drug manufacturer focused on Infectious Disease, Metabolic.
COLGATE at a Glance
- Strong track record with 87% execution quality across 81 trials
- Growing R&D activity with 30 trials in last 2 years
COLGATE's Key Drugs
COLGATE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
COLGATE's Recent FDA Approvals
New NDA/BLA approvals for COLGATE over the last two years — novel drugs only, excluding generics and label supplements.
COLGATE's Therapeutic Areas
COLGATE's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.
COLGATE's Top Competitors
COLGATE's closest competitors by therapeutic-area and drug-target overlap include Merck, Johnson & Johnson, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
COLGATE Pipeline Snapshot
COLGATE has 2 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 52/59 completed
- • Speed: 3 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1973-03-06
- Latest
- 1990-09-11
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges